Header Logo

Connection

Carl Maki to Tumor Suppressor Protein p53

This is a "connection" page, showing publications Carl Maki has written about Tumor Suppressor Protein p53.
Connection Strength

10.734
  1. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.
    View in: PubMed
    Score: 0.754
  2. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells. J Biol Chem. 2019 06 07; 294(23):9186-9197.
    View in: PubMed
    Score: 0.624
  3. Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biol Ther. 2019; 20(3):252-260.
    View in: PubMed
    Score: 0.600
  4. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340.
    View in: PubMed
    Score: 0.593
  5. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016 May 10; 7(19):27511-26.
    View in: PubMed
    Score: 0.508
  6. Modeling the Etiology of p53-mutated Cancer Cells. J Biol Chem. 2016 May 06; 291(19):10131-47.
    View in: PubMed
    Score: 0.504
  7. p53-regulated autophagy is controlled by glycolysis and determines cell fate. Oncotarget. 2015 Sep 15; 6(27):23135-56.
    View in: PubMed
    Score: 0.486
  8. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells. PLoS One. 2014; 9(11):e110844.
    View in: PubMed
    Score: 0.458
  9. Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Ce. J Biol Chem. 2012 Aug 24; 287(35):29825-36.
    View in: PubMed
    Score: 0.389
  10. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene. 2011 Nov 17; 30(46):4678-86.
    View in: PubMed
    Score: 0.361
  11. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des. 2011; 17(6):560-8.
    View in: PubMed
    Score: 0.351
  12. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem. 2010 Dec 01; 111(5):1280-90.
    View in: PubMed
    Score: 0.349
  13. Decision-making by p53 and mTOR. Aging (Albany NY). 2010 Jun; 2(6):324-6.
    View in: PubMed
    Score: 0.337
  14. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):895-905.
    View in: PubMed
    Score: 0.333
  15. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene. 2008 Sep 18; 27(42):5567-77.
    View in: PubMed
    Score: 0.293
  16. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem. 2007 May 11; 282(19):14616-25.
    View in: PubMed
    Score: 0.270
  17. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem. 2007 May 11; 282(19):14626-34.
    View in: PubMed
    Score: 0.269
  18. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity. Mol Cancer. 2006 Dec 06; 5:68.
    View in: PubMed
    Score: 0.264
  19. P53 gene alterations identified in classical Hodgkin's lymphoma cell lines. Leuk Lymphoma. 2006 Sep; 47(9):1734-5.
    View in: PubMed
    Score: 0.260
  20. Control of p53 nuclear accumulation in stressed cells. FEBS Lett. 2005 Sep 12; 579(22):4978-84.
    View in: PubMed
    Score: 0.243
  21. CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271.
    View in: PubMed
    Score: 0.212
  22. MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53. J Biol Chem. 2003 Dec 05; 278(49):49286-92.
    View in: PubMed
    Score: 0.212
  23. Stability and ubiquitination of the tumor suppressor protein p53. Methods Mol Biol. 2003; 223:27-38.
    View in: PubMed
    Score: 0.201
  24. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem. 2001 Nov 30; 276(48):45255-60.
    View in: PubMed
    Score: 0.184
  25. Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett. 2001 Feb 16; 490(3):196-201.
    View in: PubMed
    Score: 0.177
  26. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene. 2000 Nov 30; 19(51):5892-7.
    View in: PubMed
    Score: 0.174
  27. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2000 Sep; 2(9):569-73.
    View in: PubMed
    Score: 0.171
  28. Role and regulation of p53 during an ultraviolet radiation-induced G1 cell cycle arrest. Cell Growth Differ. 2000 Mar; 11(3):149-56.
    View in: PubMed
    Score: 0.165
  29. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem. 1999 Jun 04; 274(23):16531-5.
    View in: PubMed
    Score: 0.157
  30. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol. 1997 Jan; 17(1):355-63.
    View in: PubMed
    Score: 0.133
  31. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996 Jun 01; 56(11):2649-54.
    View in: PubMed
    Score: 0.128
  32. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther. 2014; 15(12):1600-12.
    View in: PubMed
    Score: 0.108
  33. Two 4N cell-cycle arrests contribute to cisplatin-resistance. PLoS One. 2013; 8(4):e59848.
    View in: PubMed
    Score: 0.102
  34. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem. 2010 Jul 23; 285(30):23105-14.
    View in: PubMed
    Score: 0.084
  35. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008 Oct 15; 68(20):8260-8.
    View in: PubMed
    Score: 0.075
  36. Physical and functional interactions between PML and MDM2. J Biol Chem. 2003 Aug 01; 278(31):29288-97.
    View in: PubMed
    Score: 0.052
  37. Transcriptional activation of bovine mimecan by p53 through an intronic DNA-binding site. Biochim Biophys Acta. 2001 Feb 16; 1517(3):333-8.
    View in: PubMed
    Score: 0.044
  38. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999 Dec 15; 59(24):6046-51.
    View in: PubMed
    Score: 0.041
  39. Absence of a radiation-induced first-cycle G1-S arrest in p53+ human tumor cells synchronized by mitotic selection. Cancer Res. 1998 May 01; 58(9):2036-41.
    View in: PubMed
    Score: 0.036
  40. Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Res. 1995 May 01; 55(9):1842-6.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.